Can Vitamin B12 Cause Cancer? Mechanism, Dose, and the Evidence

Vitamin B12 is not a carcinogen, and no study has shown that it initiates cancer. The honest answer is narrower: high-dose supplementation has been associated with roughly a threefold higher lung cancer rate in men who smoke, while dietary and multivitamin-level intake shows no such signal. The strongest human evidence comes from a 2017 cohort of 77,118 adults followed for ten years. Mechanism, dose, and the gap between correlation and causation all shape how that finding should be read.

How Vitamin B12 Works Inside a Cell

Vitamin B12, or cobalamin, is a cobalt-containing cofactor used by exactly two human enzymes. Neither enzyme damages DNA. Neither enzyme pushes a cell toward malignancy on its own. That matters, because the question of whether B12 can cause cancer implies a carcinogen, and B12 does not behave like one.

The first enzyme, methionine synthase, sits in the cytosol. It takes a methyl group from 5-methyltetrahydrofolate and hands it to homocysteine, producing methionine. That reaction regenerates folate in a form used to build thymidine, one of the four DNA letters. Methionine itself becomes S-adenosylmethionine, the cell's universal methyl donor for DNA and histone methylation.

The second enzyme, methylmalonyl-CoA mutase, works in mitochondria. It converts methylmalonyl-CoA to succinyl-CoA, clearing a byproduct of fat and protein breakdown. When B12 is missing, methylmalonic acid accumulates in blood, and that accumulation tracks with the nerve damage seen in deficiency.

Storage explains why effects lag exposure. The liver holds roughly 2 to 5 milligrams of B12, against a daily requirement of 2.4 micrograms for adults. On a diet with zero B12, those stores drain over two to five years before deficiency appears. In plain terms: the body treats B12 as a reservoir, not a daily consumable, which is why a single high dose changes blood levels far more than it changes tissue supply.

Absorption is the other constraint. Intrinsic factor, a protein made by stomach lining cells, carries B12 into the ileum, and that route saturates at about 1 to 2 micrograms per meal. Any excess above that ceiling is absorbed passively at roughly 1 percent. This single number explains most of the dose confusion later in this article.

Why a Growth Cofactor Could Feed a Tumor

B12 does not alkylate DNA, generate free radicals, or form adducts. Compare it with tobacco smoke, which delivers dozens of confirmed mutagens, or with alcohol, whose acetaldehyde metabolite is a recognized carcinogen. B12 has no comparable genotoxic pathway, and no laboratory assay shows it mutating a gene.

The plausible mechanism runs through supply, not damage. A tumor needs two things that one-carbon metabolism provides: nucleotides for replication and methyl groups for epigenetic control. B12 recycles folate and regenerates methionine, so more B12 means more capacity at both steps. In theory, relieving that bottleneck could accelerate growth of cells that are already initiated.

Laboratory work gives this idea some shape. Cancers that delete the MTAP gene accumulate methylthioadenosine and become unusually dependent on methionine salvage, a pathway that intersects with B12-dependent methylation. Methionine restriction slows some tumors in animal models. None of this has been demonstrated as a B12 effect in people.

There is also a saturation argument that cuts the other way. Cells with full B12 stores may gain nothing from additional supply, because B12 flux is not rate-limiting when the reservoir is replete. This could explain why most cohort studies find no cancer signal at ordinary intake levels while a signal appears at sustained high doses. The pathway is plausible. It is not proven.

One counterintuitive point deserves emphasis. Low B12 is the better-established cancer-adjacent state. B12 deficiency causes chromosomal breakage in dividing cells, and the autoimmune gastritis behind pernicious anemia carries its own elevated risk of gastric neuroendocrine tumors. The disease, not the vitamin, drives that risk.

Can Vitamin B12 Cause Cancer? What the Human Studies Show

The headline study is the 2017 VITAL cohort analysis by Brasky and colleagues in the Journal of Clinical Oncology. It followed 77,118 adults aged 50 to 76 in Washington State for ten years and recorded 808 lung cancer cases. Men who averaged roughly 55 micrograms per day or more of supplemental B12 over that decade had about three times the lung cancer rate of non-users. The confidence interval was wide, spanning roughly 1.6-fold to 8-fold. Women showed no association at all.

The dose detail matters more than the headline. The signal appeared in long-duration, high-dose users, not in men taking a standard multivitamin. It also strengthened with years of use, which is one of the criteria epidemiologists use to separate a real effect from a chance finding. The absence of any signal in women, however, is a genuine anomaly. It argues either for effect modification by smoking and sex hormones, or for confounding that happens to cluster in older men.

A second strand comes from a Norwegian trial published by Ebbing and colleagues in JAMA in 2009. That study randomized 6,837 patients with ischemic heart disease to folic acid plus B12, or placebo, and found about 20 percent higher cancer incidence and about 38 percent higher cancer mortality in the treated group over roughly 39 months. The critical limitation is that the treatment combined 0.8 milligrams of folic acid with 0.4 milligrams of B12. It cannot isolate B12, and folate has its own cancer literature.

A third strand is the Danish plasma study by Arendt and colleagues in 2019. It found that people in the highest category of blood B12 had roughly 20 percent higher rates of smoking- and alcohol-related cancers, but not of other cancers. That pattern is suggestive and also ambiguous, since blood B12 rises in liver disease and in some blood cancers. The marker may be following the disease rather than causing it.

Genetic studies provide the strongest counterweight. Variants such as FUT2 influence lifelong B12 levels, and Mendelian randomization uses them as a natural experiment relatively free of healthy-user bias. These analyses have not consistently reproduced the lung cancer signal. That absence argues against a large causal effect and in favor of confounding or a narrow high-dose, smoker-specific phenomenon.

The Dose Gap: 2.4 Micrograms Versus 1,000 Micrograms

Most of the public confusion comes from collapsing very different exposures into the single word "B12." The recommended dietary allowance is 2.4 micrograms daily for adults, per the Institute of Medicine's 1998 report, which also declined to set a tolerable upper intake level because no adverse effect had been observed. A typical supplement tablet contains 500 to 1,000 micrograms. That is 200 to 400 times the requirement on the label.

Absorption narrows the gap but does not close it. At 1,000 micrograms orally, only about 1 percent crosses by passive diffusion, so roughly 10 micrograms actually enters circulation. The rest is excreted. Even so, that absorbed amount is four times the daily requirement from a single tablet, and repeated dosing keeps serum levels elevated far above anything food produces.

The thresholds need reconciling in one place. A serum B12 below 200 picograms per milliliter defines deficiency, 200 to 900 is the usual reference range, and a value above roughly 1,000 usually reflects recent supplementation or a release from damaged tissue rather than a distinct clinical state.

The last row is the least discussed. Some fortified energy drinks carry 500 micrograms of B12 per can, roughly 200 times the daily requirement, and they are consumed by exactly the young male demographic that also smokes. No study has looked at that combination.

Who Is Actually at Risk, and the High-B12 Red Flag

The population with a plausible signal is narrow: current or former male smokers, over 50, who have taken 500 micrograms or more daily for a decade or longer. Heavy alcohol use appears in the Danish data as a second modifier. Outside that profile, the human evidence is null or too thin to act on.

Meanwhile, the groups who genuinely need B12 are large and under-served. Strict vegans and vegetarians absorb none from food. Adults over 60 lose stomach acid and intrinsic factor, and surveys from the Framingham Offspring Study found low or borderline B12 in a substantial minority of older adults. Long-term metformin users, people who have had bariatric surgery, and anyone on years of proton pump inhibitors all sit in the malabsorption pool. Pernicious anemia remains the classic cause.

For these people, the calculus is not close. Untreated deficiency causes irreversible spinal cord damage, and the cancer question is a distant hypothetical by comparison.

A separate clinical point cuts the other way. An unexplained high B12 in someone who takes no supplements is a finding to investigate, not to celebrate. It can signal liver disease, kidney failure, or a myeloproliferative neoplasm. Watch for these red flags:

• Serum B12 above 1,000 pg/mL with no supplement use in the past several months.
• High B12 alongside night sweats, unexplained weight loss, or early fullness after eating.
• Normal B12 but numbness, balance problems, or memory change, which warrants a methylmalonic acid test.
• A smoker taking 1,000 micrograms daily for years with no documented deficiency.
• Deficiency symptoms that persist despite oral supplements, suggesting an absorption problem.

Six Decades of B12 and Cancer Research: A Timeline

The pattern across that timeline is consistent. Every randomized signal bundles B12 with folate. Every clean B12 signal is observational. The field has been stuck in that asymmetry for nearly two decades.

What to Actually Do, and What the Evidence Cannot Tell Us

Test before you treat. A serum B12 alone is a blunt instrument, because values drift and supplementation skews them for weeks. Methylmalonic acid above roughly 0.4 micromol per liter, or elevated homocysteine, confirms functional deficiency when B12 sits in the ambiguous 200 to 400 range. Ask for those second-tier tests rather than accepting a borderline number.

Match the dose to the problem. Documented deficiency or malabsorption calls for 500 to 1,000 micrograms orally per day, or injections, and that dose is appropriate. Someone who simply wants nutritional insurance is better served by a multivitamin containing 6 to 25 micrograms, which lands in the range where no cancer signal has appeared.

Smokers should treat high-dose B12 as a decision with a rationale, not a default. If a current smoker over 50 is taking 1,000 micrograms daily for no documented reason, that is a conversation worth having with a clinician. Rechecking levels after three months of therapy, then spacing doses once stores refill, is standard practice and reduces cumulative exposure.

The limits of the evidence deserve plain statement. The VITAL cohort covered one US region, relied on self-reported supplement use, and could not fully separate B12 from B6. The Norwegian trial could not separate B12 from folic acid. Background folate fortification changed after 1998, so pre- and post-fortification cohorts are not directly comparable. No randomized trial has ever tested high-dose B12 against cancer incidence as its primary endpoint, and none is currently positioned to answer the question in smokers specifically.

That leaves a defensible position rather than a verdict. B12 does not cause cancer in any established mechanistic sense, and ordinary intake is not associated with elevated risk. Sustained high-dose use in older male smokers carries an association that is real enough to inform prescribing and too fragile to support a general warning. The mechanism by which a methylation cofactor might promote an already-damaged lung remains a hypothesis, and the marker-versus-cause problem in the plasma studies remains unresolved.